{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:37:54Z","timestamp":1791394674605,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR2020B"],"award-info":[{"award-number":["SHDC2020CR2020B"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017536","name":"Shanghai Pulmonary Hospital","doi-asserted-by":"crossref","award":["FKCX1904, FKLY20004"],"award-info":[{"award-number":["FKCX1904, FKLY20004"]}],"id":[{"id":"10.13039\/501100017536","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This trial aimed to analyse the safety, effectiveness and transcriptomic characteristics of neoadjuvant toripalimab plus chemotherapy in II\u2013III non-small-cell lung cancer (NSCLC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patient eligibility mainly involved treatment-naive, clinical stage II\u2013III and wild-type EGFR\/ALK NSCLC. The patients received 2\u20134 cycles of toripalimab (240 mg q3w) plus carboplatin-based chemotherapy. After the second treatment cycle, all patients were re-evaluated by a multidisciplinary team. Candidates eligible for surgery underwent surgery; otherwise, patients received the remaining treatment cycles. The primary endpoints were safety and major pathological response (MPR). Secondary endpoints were R0 resection rate, progression-free survival (PFS) and overall survival (OS). RNA sequencing of baseline and post-treatment samples was conducted to explore the transcriptomic characteristics of the therapeutic response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 50 eligible patients were enrolled, including 12 (24.0%) with resectable disease (RD) and 38 (76.0%) with potentially resectable disease (PRD). Treatment-related adverse events (TRAEs) were recorded in 48 cases (96.0%). Severe TRAEs occurred in 3 (6.0%) cases, including myelosuppression, drug-induced liver injury and death related to haemoptysis. The objective response rate (ORR) was 76.0%, with 8 (16.0%) patients having a complete response (CR), 30 (60.0%) partial response (PR), 10 (20.0%) stable disease (SD) and 2 (4.0%) progressive disease (PD). Surgery could be achieved in 12 (100%) patients with RD and 25 (65.8%) with PRD; 1 (2.0%) with PRD refused surgery. Therefore, R0 resection was performed for all 36 (100%) patients who underwent surgery; 20 (55.6%) achieved MPR, including 10 (27.8%) with a complete pathological response (pCR). The <jats:italic>CHI3L1<\/jats:italic> (chitinase-3-like protein 1) immunohistochemistry (IHC) expression of baseline tumour samples could predict the therapeutic response (AUC=0.732), OS (<jats:italic>P<\/jats:italic>=0.017) and PFS (<jats:italic>P<\/jats:italic>=0.001). Increased PD-1 expression, T cell abundance and immune-related pathway enrichment were observed in post-treatment samples compared to baseline in the response group (CR+PR) but not in the non-response group (SD+PD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Neoadjuvant toripalimab plus chemotherapy was safe and effective, with a high MPR and manageable TRAEs for II\u2013III NSCLC, even converting initially PRD to RD. Disparate transcriptomic characteristics of therapeutic efficiency were observed, and <jats:italic>CHI3L1<\/jats:italic> expression predicted therapeutic response and survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ChiCTR1900024014, June 22, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02696-4","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T01:02:24Z","timestamp":1672362144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II\u2013III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Xinsheng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangdong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxiong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huansha","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gening","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"issue":"13 Pt 2","key":"2696_CR1","doi-asserted-by":"publisher","first-page":"5004s","DOI":"10.1158\/1078-0432.CCR-05-9010","volume":"11","author":"JA Bogart","year":"2005","unstructured":"Bogart JA, Aronowitz JN. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy. Clin Cancer Res. 2005;11(13 Pt 2):5004s\u201310s.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"2696_CR2","doi-asserted-by":"publisher","first-page":"ii28","DOI":"10.1093\/annonc\/mdj916","volume":"17","author":"MR Migliorino","year":"2006","unstructured":"Migliorino MR, De Petris L, De Santis S, Cipri A, Belli R, Cond\u00f2 S, et al. Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease. Ann Oncol. 2006;17(Suppl 2):ii28\u201331.","journal-title":"Ann Oncol"},{"issue":"7","key":"2696_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jtho.2017.04.011","volume":"12","author":"K Chansky","year":"2017","unstructured":"Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Valli\u00e8res E, Groome P, et al. The IASLC Lung Cancer Staging Project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017;12(7):1109\u201321.","journal-title":"J Thorac Oncol"},{"issue":"21","key":"2696_CR4","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552\u20139.","journal-title":"J Clin Oncol"},{"issue":"9928","key":"2696_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet (London, England). 2014;383(9928):1561\u201371.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"2696_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6(1):8.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2696_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","volume":"21","author":"CA Shu","year":"2020","unstructured":"Shu CA, Gainor JF, Awad MM, Chiuzan C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):786\u201395.","journal-title":"Lancet Oncol"},{"issue":"21","key":"2696_CR8","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"3","key":"2696_CR9","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","volume":"275","author":"H Deng","year":"2021","unstructured":"Deng H, Liu J, Cai X, Chen J, Gaetano R, Petersen RH, et al. Radical minimally invasive surgery following immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer. Ann Surg. 2021;275(3):e600\u20132.","journal-title":"Ann Surg"},{"issue":"8","key":"2696_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","volume":"5","author":"S Lu","year":"2019","unstructured":"Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195\u2013204.","journal-title":"JAMA Oncol"},{"issue":"7","key":"2696_CR11","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mdz123","volume":"30","author":"CG Kim","year":"2019","unstructured":"Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, et al. Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104\u201313.","journal-title":"Ann Oncol"},{"issue":"9","key":"2696_CR12","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","volume":"27","author":"HQ Mai","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med. 2021;27(9):1536\u201343.","journal-title":"Nat Med"},{"issue":"19","key":"2696_CR13","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","volume":"103","author":"WJ Curran Jr","year":"2011","unstructured":"Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2696_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018;29(8):1853\u201360.","journal-title":"Ann Oncol"},{"issue":"1","key":"2696_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"17","key":"2696_CR16","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884\u201390.","journal-title":"Bioinformatics"},{"issue":"4","key":"2696_CR17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"7","key":"2696_CR18","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330.","journal-title":"Bioinformatics"},{"issue":"12","key":"2696_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"43","key":"2696_CR20","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2696_CR21","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"issue":"1","key":"2696_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.","journal-title":"Genome Biol"},{"issue":"7","key":"2696_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/ng.3581","volume":"48","author":"B Li","year":"2016","unstructured":"Li B, Li T, Pignon JC, Wang B, Wang J, Shukla SA, et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016;48(7):725\u201332.","journal-title":"Nat Genet"},{"issue":"3","key":"2696_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41588-018-0339-x","volume":"51","author":"X Hu","year":"2019","unstructured":"Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, et al. Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet. 2019;51(3):560\u20137.","journal-title":"Nat Genet"},{"issue":"21","key":"2696_CR25","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976\u201386.","journal-title":"N Engl J Med"},{"issue":"7","key":"2696_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(08)70156-6","volume":"9","author":"M Thomas","year":"2008","unstructured":"Thomas M, R\u00fcbe C, Hoffknecht P, Macha HN, Freitag L, Linder A, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008;9(7):636\u201348.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2696_CR27","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171(4):934\u2013949.e916.","journal-title":"Cell"},{"issue":"1","key":"2696_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13148-020-00907-4","volume":"12","author":"JY Kim","year":"2020","unstructured":"Kim JY, Choi JK, Jung H. Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer. Clin Epigenetics. 2020;12(1):119.","journal-title":"Clin Epigenetics"},{"key":"2696_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ejca.2022.06.034","volume":"174","author":"JP Foy","year":"2022","unstructured":"Foy JP, Karabajakian A, Ortiz-Cuaran S, Boussageon M, Michon L, Bouaoud J, et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1\/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur J Cancer (Oxford, England : 1990). 2022;174:287\u201398.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"4","key":"2696_CR30","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782\u201395.","journal-title":"Immunity"},{"issue":"11","key":"2696_CR31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal-Rubio J, D\u00f3mine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413\u201322.","journal-title":"Lancet Oncol"},{"issue":"26","key":"2696_CR32","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, et al. SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol. 2021;39(26):2872\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2696_CR33","doi-asserted-by":"publisher","first-page":"1996000","DOI":"10.1080\/2162402X.2021.1996000","volume":"10","author":"ZR Zhao","year":"2021","unstructured":"Zhao ZR, Yang CP, Chen S, Yu H, Lin YB, Lin YB, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021;10(1):1996000.","journal-title":"Oncoimmunology"},{"issue":"10308","key":"2696_CR34","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357.","journal-title":"Lancet"},{"issue":"12","key":"2696_CR35","first-page":"3417","volume":"9","author":"BW Morrison","year":"1994","unstructured":"Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene. 1994;9(12):3417\u201326.","journal-title":"Oncogene"},{"issue":"5","key":"2696_CR36","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1084\/jem.20081271","volume":"206","author":"CG Lee","year":"2009","unstructured":"Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of breast regression protein 39 (BRP-39)\/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009;206(5):1149\u201366.","journal-title":"J Exp Med"},{"key":"2696_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-physiol-012110-142250","volume":"73","author":"CG Lee","year":"2011","unstructured":"Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin and chitinase\/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479\u2013501.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"2696_CR38","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1038\/s41467-021-25188-0","volume":"12","author":"T Cascone","year":"2021","unstructured":"Cascone T, Weissferdt A, Godoy MCB, William WN Jr, Leung CH, Lin HY, et al. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021;12(1):5045.","journal-title":"Nat Commun"},{"issue":"7","key":"2696_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"SB Coffelt","year":"2016","unstructured":"Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431\u201346.","journal-title":"Nat Rev Cancer"},{"key":"2696_CR40","doi-asserted-by":"publisher","first-page":"14381","DOI":"10.1038\/ncomms14381","volume":"8","author":"J Kargl","year":"2017","unstructured":"Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017;8:14381.","journal-title":"Nat Commun"},{"issue":"3-4","key":"2696_CR41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/jnci\/88.3-4.183","volume":"88","author":"EA Zang","year":"1996","unstructured":"Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88(3-4):183\u201392.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2696_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S1470-2045(01)00457-0","volume":"2","author":"JM Siegfried","year":"2001","unstructured":"Siegfried JM. Women and lung cancer: does oestrogen play a role? Lancet Oncol. 2001;2(8):506\u201313.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2696_CR43","first-page":"2141","volume":"62","author":"LP Stabile","year":"2002","unstructured":"Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res. 2002;62(7):2141\u201350.","journal-title":"Cancer Res"},{"issue":"2","key":"2696_CR44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/IGC.0000000000000875","volume":"27","author":"L Yang","year":"2017","unstructured":"Yang L, Huang F, Mei J, Wang X, Zhang Q, Wang H, et al. Posttranscriptional control of PD-L1 expression by 17\u03b2-estradiol via PI3K\/Akt signaling pathway in ER\u03b1-positive cancer cell lines. Int J Gynecol Cancer. 2017;27(2):196\u2013205.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2696_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/intimm\/dxl151","volume":"19","author":"MJ Polanczyk","year":"2007","unstructured":"Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1). Int Immunol. 2007;19(3):337\u201343.","journal-title":"Int Immunol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02696-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T01:02:54Z","timestamp":1672362174000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02696-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02696-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Shanghai Pulmonary Hospital (19216XW-4). Written informed consent was obtained from all patients before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}